Drug
Linagliptin clinical trials
Also written BI 1356 and Trajenta.
- studies test it
- 129
- open now
- 3
- in phase 3
- 38
- first study started
- 2004
Keep track of what changes. Save the Linagliptin studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
129 studies that test it; most in 2008 (19)
| Year | Studies |
|---|---|
| 2004 | 1 |
| 2005 | 5 |
| 2006 | 4 |
| 2007 | 2 |
| 2008 | 19 |
| 2009 | 7 |
| 2010 | 13 |
| 2011 | 3 |
| 2012 | 7 |
| 2013 | 15 |
| 2014 | 12 |
| 2015 | 5 |
| 2016 | 7 |
| 2017 | 9 |
| 2018 | 3 |
| 2019 | 2 |
| 2020 | 2 |
| 2021 | 2 |
| 2022 | 2 |
| 2023 | 1 |
| 2024 | 2 |
| 2025 | 3 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 52
- Phase 2
- 7
- Phase 3
- 38
- Phase 4
- 30
- No phase
- 4
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 89 · Other 40
Boehringer Ingelheim (74) · Humanis Saglık Anonim Sirketi (4) · Universidad de Guanajuato (4) · Dong Wha Pharmaceutical Co. Ltd. (3) · Emory University (2) · Profil Institut für Stoffwechselforschung GmbH (2) · Hoffmann-La Roche (2) · Rabin Medical Center (2)
Often tested with
Tested in the same studies.
Metformin (29) · Empagliflozin (23) · Pioglitazone (5) · Sitagliptin (2) · Insulin Glargine (2) · Gliclazide (2) · Atezolizumab (2) · Cobimetinib (2)
Studies
Open first, then newest update. How each study uses Linagliptin is read from its arms, and is right about nine times in ten.
Testing it · 129
- Glycemic Control With Triple Pathway Approach Through Empagliflozin, Linagliptin and Metformin CombinationRecruitingPhase 4Nabiqasim Industries (Pvt) LtdNCT06862739Written as Empagliflozin+Linagliptin+Metformin
- Metformin, Empagliflozin With Sitagliptin vs Linagliptin in Type 2 DiabetesEnrolling by invitationPhase 4Bahria UniversityNCT07452913Written as Metformin + Empagliflozin + Linagliptin
- The Bioequivalence Study of Linagliptin 5 mg Film-coated Tablet in Healthy Thai VolunteersNot yet recruitingPhase 1International Bio serviceNCT06243809Written as Linagliptin 5 mg Oral Tablet
- Bioequivalence Study to Compare Empagliflozin/Linagliptin/Metformin HCl25 mg/5 mg/1000 mg Extended Release Tablet Versus Trijardy® XR 25 mg/5 mg/1000 mg Extended- Release TabletsCompletedPhase 1Humanis Saglık Anonim SirketiNCT07872358Written as Empagliflozin/Linagliptin/Metformin HCl Extended Release Tablet
- Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes.CompletedPhase 4Fundación para la Investigación del Hospital Clínico de ValenciaNCT06851962Written as linagliptin
- LIGHT-MCI Trial: GLP-1 Agonist, SGLT2 Inhibitor, and DPP-4 Inhibitor for MCI Remission in Type 2 DiabetesCompletedNot applicableThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolNCT05313529Written as Linagliptin
- A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)TerminatedPhase 1/2Hoffmann-La RocheNCT03281369Written as Linagliptin
- Bioequivalence Study to Compare Empagliflozin/Linagliptin/Metformin HCl 25 mg/5 mg/1000 mg Extended Release Tablet Versus Trijardy® XR 25 mg/5 mg/1000 mg Extended- Release TabletsCompletedPhase 1Humanis Saglık Anonim SirketiNCT07691203Written as Empagliflozin/Linagliptin/Metformin HCl Extended Release Tablet
- A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer)TerminatedPhase 1/2Hoffmann-La RocheNCT03337698Written as Linagliptin
- Bioequivalence Study to Compare Empagliflozin/Linagliptin/Metformin HCL 25mg/5mg/1000mg Extended-Release Tablets Versus Trijardy® XR Extended Release Film Coated TabletsCompletedPhase 1Humanis Saglık Anonim SirketiNCT07213895Written as Empagliflozin/Linagliptin/Metformin HCL
- Bioequivalence Study to Compare Empagliflozin + Linagliptin 25 mg/5 mg Film-coated Tablets Versus Glyxambi 25 mg/ 5 mg Film-coated TabletsCompletedPhase 1Humanis Saglık Anonim SirketiNCT06932159Written as Empagliflozin + Linagliptin film-coated tablets
- Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 DiabetesCompletedPhase 3Boehringer IngelheimNCT01734785Written as Linagliptin
- Diabetes Study of Linagliptin and Empagliflozin in Children and Adolescents (DINAMO)TMCompletedPhase 3Boehringer IngelheimNCT03429543Written as Linagliptin
- Efficacy and Safety of Empagliflozin in NODATTerminatedPhase 4RenJi HospitalNCT03642184Written as Linagliptin
- A Pharmacokinetic Study of DW6013 (FDC of Linagliptin and Metformin) in Healthy Adult Volunteers in Fed ConditionCompletedPhase 1Dong Wha Pharmaceutical Co. Ltd.NCT05874180Written as DW6013
- A Pharmacokinetic Study of DW6013 (FDC of Linagliptin and Metformin) in Healthy Adult VolunteersCompletedPhase 1Dong Wha Pharmaceutical Co. Ltd.NCT05874167Written as DW6013
- The Effect of LINAGLIPTIN on Inflammation, Oxidative Stress and Insulin Resistance in Obese Type 2 Diabetes SubjectsCompletedPhase 4University at BuffaloNCT02372630Written as Linagliptin
- Linagliptin's Effect on CD34+ Stem CellsCompletedPhase 4George Washington UniversityNCT02467478Written as Linagliptin
- Efficacy of Empagliflozin or Linagliptin as an Alternative to Metformin for Treatment of Polycystic Ovary SyndromeStatus unknownPhase 4Alexandria UniversityNCT05200793Written as Linagliptin 10 mg
- Renal Actions of Combined Empagliflozin and LINagliptin in Type 2 diabetESStatus unknownPhase 4M.H.H. KramerNCT03433248Written as LINA/EMPA 5/10 mg QD (N=22)
See all 129 studies that test Linagliptin →
Given in every arm · 5 — Linagliptin is usual care beside what is tested
- A Comparison of Two Treatment Strategies in Older Participants With Type 2 Diabetes Mellitus (T2DM)TerminatedPhase 4Eli Lilly and CompanyNCT02072096Written as Linagliptin
- The Effect of Combination of Mosapride and DPP-4 Inhibitor on Plasma Concentration of Incretin HormonesCompletedPhase 4Seoul National University HospitalNCT02180334Written as Linagliptin
- Relative Bioavailability of a Linagliptin+Metformin Fixed Dose Combination Tablet Administered With and Without Food to Healthy Male and Female SubjectsCompletedPhase 1Boehringer IngelheimNCT02223026Written as Linagliptin/metformin FDC
- Bioavailability of BI 1356 After Co-administration With Ritonavir Compared to the Bioavailability of BI 1356 Alone in Healthy Male VolunteersCompletedPhase 1Boehringer IngelheimNCT02183441Written as BI 1356
- Linagliptin and Metformin Versus Linagliptin in Newly Diagnosed, Untreated Type 2 DiabetesCompletedPhase 4Boehringer IngelheimNCT01512979Written as linagliptin
As the comparator · 14 — what is tested is compared with Linagliptin
- Efficacy and Safety of Madalena Association in the Treatment of Type II Diabetes MellitusRecruitingPhase 3EMSNCT04670666Written as EMPAGLIFLOZIN + LINAGLIPTIN
- Effect of Empagliflozin vs Linagliptin on Glycemic Outcomes,Renal Outcomes & Body Composition in Renal Transplant Recipients With Diabetes MellitusRecruitingNot applicableMedanta, The Medicity, IndiaNCT06095492Written as Linagliptin
- Empagliflozin Versus Linagliptin in Renal Ransplant Recipients With Diabetes MellitusNot yet recruitingNot applicableMedanta, The Medicity, IndiaNCT06098625Written as Linagliptin 5 mg Oral Tablet
- Efficacy and Safety of LID104 in the Treatment of Type II Diabetes MellitusNot yet recruitingPhase 3EMSNCT05886088Written as Linagliptin
- Study on Improving Blood Glucose Homeostasis With Dorzagliatin Tablets in the Treatment of Type 2 Diabetes Mellitus Patients With Moderate to Severe Chronic Renal InsufficiencyWithdrawnNot applicableSun Yat-sen UniversityNCT07786571Written as Linagliptin
- HSK7653 Metformin Add-on Study in Patients With Type 2 Diabetes MellitusCompletedPhase 3Sichuan Haisco Pharmaceutical Group Co., LtdNCT04564872Written as Linagliptin 5 mg QD
- Efficacy and Safety of Lima Association in the Control of Type II Diabetes Mellitus.WithdrawnPhase 3EMSNCT03766750Written as Tradjenta
- Study of TQ-F3083 Capsules in Subjects With Type 2 Diabetes MellitusStatus unknownPhase 2Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT03986073Written as Linagliptin tablet
- Teneligliptin Versus Linagliptin in Diabetes Mellitus Type Two PatientsCompletedPhase 4Handok Inc.NCT03011177Written as Linagliptin
- Phase IV Clinical Trial to Investigate the Effect on Blood Glucose of Evogliptin in Patients With Type 2 Diabetes(EVERGREEN)CompletedPhase 4Dong-A ST Co., Ltd.NCT02974504Written as Linagliptin
- The Efficacy of Sodium-glucose Co-transporter 2 Inhibitor or Dipeptidyl Peptidase-4 Inhibitor in Type 2 Diabetes Patients With Premix InsulinStatus unknownPhase 4Mackay Memorial HospitalNCT03458715Written as DPP4 inhibitor (Linagliptin 5 MG)
- A One-year Randomized Controlled Trial Evaluating the Impact of Pioglitazone Versus Linagliptin on Bone Turnover MarkersStatus unknownPhase 4National Taiwan University HospitalNCT02429232Written as Linagliptin
- Efficacy and Safety of Empagliflozin (BI 10773) / Linagliptin (BI 1356) Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes PatientsCompletedPhase 3Boehringer IngelheimNCT01422876Written as linagliptin
- Relative Bioavailability of Two Fixed Dose Combination Tablets of Linagliptin/Pioglitazone Compared With Single Linagliptin and Pioglitazone Tablets Administered Together to Healthy Male and Female SubjectsCompletedPhase 1Boehringer IngelheimNCT02183636Written as Linagliptin tablet
Codes
What other systems call Linagliptin · ClinicalTrials.gg INT006598
- MeSH (NLM) D000069476LinagliptinConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 3X29ZEJ4R2LINAGLIPTINConfirmed FDA, NLM, Wikidata
- RxNorm 1100699Confirmed FDA, Wikidata
- Wikidata Q909745linagliptinConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C83887LinagliptinOne source FDA
- DrugBank DB08882One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000069476 | Linagliptin | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 3X29ZEJ4R2 | LINAGLIPTIN | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1100699 | — | Confirmed FDA, Wikidata |
| Wikidata | Q909745 | linagliptin | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C83887 | Linagliptin | One source FDA |
| DrugBank | DB08882 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.